Literature DB >> 21640623

Mechanisms regulating superoxide generation in experimental models of phenylketonuria: an essential role of NADPH oxidase.

Lihua Lu1, Xuefan Gu, Duan Li, Lili Liang, Zhen Zhao, Jialin Gao.   

Abstract

This study was designed to investigate whether nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, a superoxide-producing enzyme, could be involved in phenylketonuria (PKU)-associated oxidative stress. A Pah(enu2)-BTBR PKU mouse model, and an in vitro cell culture model of PKU mimicking high phenylalanine insults in PKU, were employed for this study. The concentration of phenylalanine in mouse cerebral cortex was determined by liquid chromatography-tandem mass spectrometry. Superoxide production was displayed with dihydroethidium staining. NADPH oxidase expression level was measured by real-time RT-PCR, Western blotting and immunofluorescence. NADPH oxidase activity was measured by the colorimetric method. The phenylalanine concentrations in cerebral cortices of PKU mice were significantly higher than those in wild-type control mice. Similar results concerning superoxide production and NADPH oxidase protein expression and activity, were also found in this brain region. In addition, it was found that cerebral cortical neurons subjected to an in vitro high phenylalanine insult, displayed increased superoxide production accompanied by increases of NADPH oxidase protein expression and activity. Pretreatment with the inhibitor of this oxidase (diphenylene iodonium or apocynin) prevented this superoxide-increasing effect. Collectively, these findings provide evidence that NADPH oxidase might be a key enzyme involved in enhanced superoxide production in PKU and suggest that it may be a potential therapeutic target in neuroprotective strategies against phenylalanine-evoked oxidative brain injury in PKU.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640623     DOI: 10.1016/j.ymgme.2011.05.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  AMP-activated protein kinase activation in mediating phenylalanine-induced neurotoxicity in experimental models of phenylketonuria.

Authors:  Lihua Lu; Xiaoming Ben; Lingling Xiao; Min Peng; Yongjun Zhang
Journal:  J Inherit Metab Dis       Date:  2017-12-11       Impact factor: 4.982

Review 3.  Insights from Animal Models on the Pathophysiology of Hyperphenylalaninemia: Role of Mitochondrial Dysfunction, Oxidative Stress and Inflammation.

Authors:  Angela T S Wyse; Tiago M Dos Santos; Bianca Seminotti; Guilhian Leipnitz
Journal:  Mol Neurobiol       Date:  2021-02-06       Impact factor: 5.590

Review 4.  Oxidative stress in phenylketonuria-evidence from human studies and animal models, and possible implications for redox signaling.

Authors:  Vanessa Trindade Bortoluzzi; Carlos Severo Dutra Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

5.  cAMP/PKA-CREB-BDNF signaling pathway in hippocampus of rats subjected to chemically-induced phenylketonuria.

Authors:  Cigdem Cicek; Emine Eren-Koçak; Pelin Telkoparan-Akillilar; Muslum Gok; Ebru Bodur
Journal:  Metab Brain Dis       Date:  2021-11-20       Impact factor: 3.584

Review 6.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

7.  Metabolomics analysis reveals perturbations of cerebrocortical metabolic pathways in the Pahenu2 mouse model of phenylketonuria.

Authors:  Li-Hua Lu; Zheng-Xiang Xia; Jia-Lin Guo; Ling-Ling Xiao; Yong-Jun Zhang
Journal:  CNS Neurosci Ther       Date:  2019-08-31       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.